Small molecule · Inhibitor of lysine-specific demethylase 1 (KDM1A) · developed by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
EXS74539 (REC-4539) is an orally bioavailable, reversible, CNS-penetrant inhibitor of the histone demethylase LSD1 (KDM1A). By blocking LSD1, it alters histone H3K4 and H3K9 methylation, affecting the expression of tumor-related genes. It is being studied in solid tumors, including small cell lung cancer, non-small cell lung cancer, prostate, ovarian, renal, head and neck, hepatic, gastric and triple-negative breast cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07517198 | Phase 1 | Solid Tumor | Recruiting | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Hepatic CancerHigh Grade Neuroendocrine CancerNon-small Cell Lung Cancer (NSCLC)Ovarian CancerProstate CancerRenal Carcinoma (Clear and Non-clear Cell)Small Cell Carcinomas of Non-lung OriginSmall Cell Lung Cancer (SCLC)Solid TumorTriple-negative Breast Cancer (TNBC)
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →